BPC-157 Peptide Nasal Spray

BPC-157 is a 15-residue synthetic peptide, GEPPPGKPADDAGLV, whose sequence was found in a protein from human gastric juice. In this listing it comes as a sterile solution in bacteriostatic water, packed in a metered nasal spray bottle with the amount and concentration printed on the label. The research on BPC-157 is mostly rat and cell work on gut and soft-tissue injury, and a separate literature asks whether molecules sprayed into the nose can reach the brain.

Specifications

What is in the bottle

The bottle holds BPC-157 dissolved in bacteriostatic water, which contains 0.9% benzyl alcohol as an antimicrobial preservative. The safety data sheet records the peptide content as stated on the label and below 10% w/v. It is the same sequence, theoretical mass 1419.6 Da, as in the freeze-dried vials. BPC-157 itself is not classified as hazardous, while benzyl alcohol carries warnings for harm if swallowed or inhaled, serious eye irritation and allergic skin reactions.

Keep the bottle upright with its cap on, at 2 to 8 °C and away from light, and do not freeze it. General guidance on keeping peptides and their solutions is in peptide storage and stability.

What the research covers

Sikiric’s group in Zagreb described BPC-157 as an anti-ulcer peptide that remains stable in human gastric juice, with effects on gut lesions in rats and on the nitric oxide, dopamine and serotonin systems¹. In 2018 Seiwerth and colleagues, co-authors of that review, compared it with EGF, FGF and VEGF and argued that it was the only one of the four that worked consistently across their gut injury models, before turning to tendon, ligament, muscle and bone². That literature is large, but it comes mainly from one group and mainly from rats, and none of it concerns the nose.

A spray raises a different question. Lisbeth Illum wrote in 2004 that the blood-brain barrier keeps most polar and large drugs out of the brain, and that the olfactory pathway had drawn interest as a way around it³. She cited many animal studies, mostly in rats, that showed transport from nose to brain, and human studies with cerebrospinal fluid sampling that, in her opinion, confirmed a direct pathway was likely³. Nothing cited here gave BPC-157 by the nasal route, so whether a 1419.6 Da peptide crosses the nasal lining, and where it goes if it does, has not been measured. The BPC-157 research guide summarises the wider literature.

How each lot is tested

Every lot is tested in PrymaLab’s own laboratory in Ashland, Kentucky before release: RP-HPLC for purity, LC-MS for identity, Karl Fischer titration for water, LAL for endotoxin and USP <71> for sterility. Published certificates are listed on the results page and can be checked by number and key on the verify page. The certificate covers the peptide lot used to fill the bottle, not the finished solution. These are in-house results from PrymaLab Analytical, not an independent test, and the lab is not accredited to ISO 17025. The third-party testing guarantee on this page still applies: if any independent laboratory finds the wrong compound, or less than the stated purity or amount, the order is refunded and the cost of the test is reimbursed.

Frequently asked questions

References

1. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-32. DOI · PubMed
2. Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des. 2018;24(18):1972-1989. DOI · PubMed
3. Illum L. Is nose-to-brain transport of drugs in man a reality?. J Pharm Pharmacol. 2004;56(1):3-17. DOI · PubMed